These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29930021)

  • 1. Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
    Orme RC; Parker WAE; Thomas MR; Judge HM; Baster K; Sumaya W; Morgan KP; McMellon HC; Richardson JD; Grech ED; Wheeldon NM; Hall IR; Iqbal J; Barmby D; Gunn JP; Storey RF
    Circulation; 2018 Sep; 138(13):1290-1300. PubMed ID: 29930021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial.
    Marian MJ; Abu Daya H; Chatterjee A; Al Solaiman F; Sasse MF; Fonbah WS; Workman RW; Johnson BE; Carlson SE; Brott BC; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2019 Dec; 8(23):e012844. PubMed ID: 31766977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
    Waksman R; Maya J; Angiolillo DJ; Carlson GF; Teng R; Caplan RJ; Ferdinand KC
    Circ Cardiovasc Interv; 2015 Jul; 8(7):e002232. PubMed ID: 26152562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
    Franchi F; Rollini F; Rivas Rios J; Rivas A; Agarwal M; Kureti M; Nagaraju D; Wali M; Shaikh Z; Briceno M; Nawaz A; Moon JY; Been L; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2018 Jun; 137(23):2450-2462. PubMed ID: 29526833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
    Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
    J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
    Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
    Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
    Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
    Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.
    Pelletier-Galarneau M; Hunter CRRN; Ascah KJ; Beanlands RSB; Dwivedi G; deKemp RA; Chow BJW; Ruddy TD
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation.
    Marcano AL; Gracida M; Roura G; Gomez-Lara J; Romaguera R; Teruel L; Fuentes L; Muntané-Carol G; Meroño O; Sosa SG; Gómez-Hospital JA; Comin-Colet J; Ferreiro JL
    Front Cardiovasc Med; 2022; 9():1057331. PubMed ID: 36483622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes.
    Liu Z; Tian R; Wang Y; Chen Q; Li J; Xu L; Zhang S
    Thromb Haemost; 2020 Aug; 120(8):1221-1229. PubMed ID: 32668483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
    Wu X; Liu G; Lu J; Zheng XX; Cui JG; Zhao XY; Huang XH
    Int Heart J; 2017 Apr; 58(2):167-173. PubMed ID: 28321022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High and low on-treatment platelet reactivity to P2Y
    Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
    Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
    Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
    Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
    Campo G; Vieceli Dalla Sega F; Pavasini R; Aquila G; Gallo F; Fortini F; Tonet E; Cimaglia P; Del Franco A; Pestelli G; Pecoraro A; Contoli M; Balla C; Biscaglia S; Rizzo P; Ferrari R
    Thromb Haemost; 2017 Mar; 117(6):1208-1216. PubMed ID: 28331925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.